• No se han encontrado resultados

técitamente en la expropiacidn, el tribunal evaluara lo que se deba expropiar luego de oir el concepto de los peritos

In document La reforma agraria en Panamá (página 67-70)

schizophrenia has never been met (though patient may have tactile or olfactory hallucinations if they are related to the delusional theme)

C. functioning not markedly impaired; behaviour not obviously odd or bizarre D. if mood episodes occur concurrently with delusions, total duration has been brief relative to duration of the delusional periods

E. the disturbance is not due to the direct physiological effects of a substance or GMC

subtypes: erotomanic, grandiose, jealous, persecutory, somatic, mixed, unspecified

treatment:

psychotherapy, antipsychotics, antidepressants

prognosis: chronic, unremitting course but high level of functioning

Folstein Mini Mental State Exam (MMSE) to assess Dementia:

Orientation (time and place) – 5 points

Memory (immediate and delayed recall) – 5 points Attention and Concentration

Language (comprehension, reading, writing, repetition, naming)

Spacial ability (intersecting pentagons)

Gross screen for cognitive dysfunction: Total score is out of 30; <24 abnormal 20-24 mild, 10-19 moderate,

<10 severe

See attached Form

DSM-IV-TR Diagnostic Criteria for Dementia (Alzheimer’s Type) A. the development of multiple cognitive deficits manifested by both

1. memory impairment (impaired ability to learn new information or to recall previously learned information)

2. >1 of the following cognitive

disturbances:

o aphasia (language disturbance) o apraxia (impaired

ability to carry out motor activities despite intact motor function) o agnosia (failure to

recognize or identify objects despite intact sensory function) o disturbance in

executive functioning (i.e.

planning, organizing, sequencing, abstracting) B. the cognitive deficits in Criteria A1 and A2 each cause significant impairment in social or occupational functioning and represent a significant decline from a previous level of functioning

C. the course is

characterized by gradual onset and continuing cognitive decline

D. the cognitive deficits in Criteria A1 and A2 are not due to any of the following:

 1. other central nervous system conditions that cause progressive deficits in memory and cognition

 2. systemic conditions that are known to cause dementia

 3. substance-induced conditions

E. the deficits do not occur exclusively during the course of a delirium F. the disturbance is not better accounted for by another Axis I disorder

Investigations (rule out reversible causes)

standard: as in Delirium

 as indicated: VDRL, HIV, SPECT, CT head in dementia

 indications for CT head, as in Delirium section plus: age <60, rapid onset (unexplained decline in cognition or function over 1-2 months), dementia of relatively short duration (<2 years), recent significant head trauma, unexplained neurological symptoms (new onset of severe

headache/seizures) Management

 treat medical problems and prevent others

 provide orientation cues (e.g. clock, calendar)

 provide education and support for patient and family (day programs, respite care, support groups, home care)

 consider long-term care plan (nursing home) and power of attorney/living will

 inform Ministry of Transportation about patient’s inability to drive safely

 consider pharmacological therapy

o cholinesterase inhibitors (e.g.

donepezil

(Aricept)) for mild to severe disease o glutamatergic

NMDA receptor antagonist (e.g memantine) for moderate to severe disease o low-dose

neuroleptics (haloperidol, risperidone) and antidepressants if behavioural or emotional symptoms prominent - start low and go slow o reassess

pharmacological therapy every 3 months

Substance Abuse History Validated screening questionnaire (Alcohol):

C ever felt the need to Cut down on drinking?

A ever felt Annoyed at criticism of your drinking?

G ever feel Guilty about your drinking?

E ever need a drink first thing in morning (Eye opener)?

 for men, a score of >2 is a positive screen and for women, a score of >1 is a positive screen

 if positive CAGE, then assess further to distinguish between problem drinking and alcohol dependence General Assessment

 When was the last drink?

 Do you have to drink more to get the same effect?

 Do you get shaky or nauseous when you stop drinking?

 Have you had a withdrawal seizure?

 How much time and effort do you put into obtaining alcohol?

 Has your drinking affected your ability to work, go to school, or have relationships?

 Have you suffered any legal consequences?

 Has your drinking caused any medical problems?

Moderate Drinking Men: 2 or less/day Women: 1 or less/day Elderly: 1 or less/day Drinking Problem Drinking above the

recommended guidelines, associated with:

 Drinking to or reduce depression or anxiety

 Loss of interest in food

 Lying/hiding drinking habits

 Drinking alone

 Injuring self or others while intoxicated

 Were drunk more than three or four times last year

 Increasing tolerance

 Withdrawal symptoms:

feeling irritable,

resentful, unreasonable when not drinking

 Experiencing medical, social, or financial problems caused by drinking

Adverse Medical Conditions -alcohol

GI: gastritis, dyspepsia, pancreatitis, liver disease, bleeds, diarrhea,

oral/esophageal cancer Cardiac: hypertension, alcoholic cardiomyopathy Neurologic: Wernicke-Korsakoff syndrome, peripheral neuropathy Hematologic: anemia, coagulopathies

Other: trauma, insomnia, family violence,

anxiety/depression, social/family dysfunction, sexual dysfunction, fetal damage

Investigations

 GGT and MCV for baseline and follow-up monitoring

 AST, ALT (usually, AST:ALT approaches 2:1 in an alcoholic)

 CBC (anemia,

thrombocytopenia), PT (decreased clotting factors production by liver)

Management

 intervention should be consistent with patient’s motivation for change (motivational

interviewing)

 regular follow-up is crucial

 10% of patients in alcohol withdrawal will have seizures or delirium tremens

 Alcoholics

Anonymous/12-step program

 outpatient/day programs for those with chronic, resistant problems

 family treatment (Al-Anon, Alateen, screen for spouse/child abuse)

 in-patient program if:

 dangerous or highly unstable home environment

 severe

medical/psychiatric problem

 addiction to drug that may require

in-patient detoxification

 refractory to other treatment programs

 Non Pharmacological

 behaviour modification:

hypnosis, relaxation training, aversion therapy,

assertiveness training, operant conditioning

 supportive services:

half-way houses, detoxification centres, Alcoholics Anonymous

 psychotherapy, motivational interviewing

 medications important as

adjunctive treatment:

SSRIs, ondansetron, topiramate

 pharmacologic

 diazepam for withdrawal

 disulfiram (Antabuse) o blocks

conversion of acetaldehyde to acetic acid

(which leads to flushing, headache, nausea/vomiti ng,

hypotension if alcohol is ingested)

 naltrexone

o competitive opioid antagonist that reduces cravings and pleasurable effects of drinking o note:

prescription opioids become ineffective;

may trigger withdrawal in

opioid-dependent patients Signs of Alcohol withdrawl (Delerium Tremens)

Autonomic hyperactivitiy (diaphoresis, tachycardia, increased respiration) Hand tremor

Insomnia

Psychomotor agitation Anxiety

Nausea or vomiting Grand mal seizures Visual/tactile/auditory hallucinations

Persecutory delusions Management of Alcohol Withdrawal

Monitor using the Clinical Institute Withdrawal Assessment for Alcohol (CIWA-A) scoring system.

Areas of assessment include

 nausea and vomiting

 paroxysmal sweats

 tactile disturbances

 visual disturbances

 tremor

 anxiety

 auditory disturbances

 headache, fullness in head

 agitation

o orientation and clouding of sensorium

 all categories are scored from 0-7 (except:

orientation/sensorium 0-4), maximum score of 67

 mild <10

 moderate 10-20

 severe

>20

 basic treatment protocol using CIWA-A scale

o diazepam 20 mg PO q1-2h prn until CIWA-A <10 points; tapering dose not required o observe 1-2 h

after last dose and re-assess on CIWA-A scale o thiamine 100 mg

IM then 100 mg PO OD for 3 days o supportive care

(hydration and nutrition)

 if history of withdrawal seizures

o diazepam 20 mg q1h for minimum of three doses regardless of subsequent CIWA scores

 if history of seizure disorder or multiple withdrawal seizures despite diazepam, use anti-seizure medication (e.g. Dilantin)

 if oral diazepam not tolerated

o diazepam 2-5 mg IV/min –

maximum 10-20 mg q1h; or lorazepam SL

 if >65 yr or severe liver disease, severe asthma,

or respiratory failure are present, use short acting benzodiazepine

o lorazepam PO/SL/IM 1-4 mg q1-2h

 if hallucinosis present o haloperidol 2-5

mg IM/PO q1-4h – max 5 doses/day or atypical antipsychotics (olanzapine, risperidone) o diazepam 20 mg

x 3 doses as seizure prophylaxis (haloperidol lowers seizure threshold)

 admit to hospital if:

o still in withdrawal after >80 mg of diazepam

o delirium tremens, recurrent

arrhythmias, or multiple seizures o medically ill or

unsafe to discharge home Wernicke-Korsakoff Syndrome

 alcohol-induced amnestic disorders due to thiamine deficiency

 necrotic lesions –

mammillary bodies, thalamus, brain stem

 Wernicke’s encephalopathy (acute and

reversible): triad of nystagmus (CN VI palsy), ataxia and confusion

 Korsakoff’s syndrome (chronic and only 20%

reversible with treatment):

anterograde amnesia

and confabulations;

cannot occur during an acute delirium or dementia and must persist beyond usual duration of

intoxication/withdraw al

 management

o Wernicke’s : thiamine 100 mg PO OD x 1-2 weeks o Korsakoff’s

: thiamine 100 mg PO bid/tid x 3-12 mon Prognosis

 relapse is common and should not be viewed as failure

 monitor regularly for signs of relapse

 25-30% of abusers exhibit spontaneous improvement over 1 year

 60-70% of individuals with jobs and families have an improved quality of life 1 year

post-treatment Cocaine Intoxication

 elation, euphoria, pressured speech, restlessness,

sympathetic stimulation (i.e. tachycardia,

mydriasis, sweating)

 prolonged use may result in paranoia and

psychosis Overdose

 medical emergency:

hypertension,

tachycardia, tonic-clonic seizures, dyspnea, and ventricular arrhythmias

 treatment with IV diazepam to control

seizures and propanolol or labetalol to manage hypertension and arrhythmias Withdrawal

 initial crash (1-48 hrs):

increased sleep, increased appetite

 withdrawal (1-10 wks):

dysphoric mood plus fatigue, irritability, vivid, unpleasant dreams, insomnia or

hypersomnia,

psychomotor agitation or retardation

 complications: relapse, suicide (significant increase in suicide during withdrawal period)

 management: supportive management

Treatment of Chronic Abuse

 optimal treatment not established

 psychotherapy, group therapy, and behaviour modification useful in maintaining abstinence

 studies of dopamine agonists to block cravings show inconsistent results Complications

 cardiovascular:

arrhythmias, MI, CVA, ruptured AA

 neurologic: seizures

 psychiatric: psychosis, paranoia, delirium, suicidal ideation Ganja

 marijuana is the most often used illicit drug

 psychoactive substance

delta-9-tetrahydrocannabinol (9 -THC)

 smoking is the most common mode of self-administration

 intoxication characterized by tachycardia, conjunctival vascular engorgement, dry mouth, increased appetite, increased sense of well-being, euphoria/laughter, muscle relaxation, impaired performance on

psychomotor tasks including driving

 high doses can cause depersonalization, paranoia, and anxiety

 may trigger psychosis and schizophrenia in predisposed individuals

 chronic use associated with tolerance and an apathetic, amotivational state

 cessation does not produce significant withdrawal phenomenon

 treatment of dependence includes behavioural and psychological interventions to maintain an abstinent state

Medical Uses of Ganja Anorexia-cachexia (AIDS, cancer)

Spasticity, muscle spasms (multiple sclerosis, spinal cord injury)

Levodopa-induced dyskinesia (Parkinson's Disease)

Controlling tics and obsessive-compulsive behaviour (Tourette's syndrome)

Reducing intra-ocular pressure (glaucoma) Mood Disorders

Mood disorders are defined by the presence of mood episodes

 mood episodes represent a combination of

symptoms comprising a predominant mood state that is abnormal in

quality or duration;

examples include: major depressive, manic, mixed, hypomanic

 types of mood disorders include:

o depressive (major depressive disorder, dysthymia) o bipolar (bipolar I/II

disorder, cyclothymia) o secondary to

GMC, substances, medications Secondary Causes of Mood Disorders

 infectious:

encephalitis/meningitis, hepatitis, pneumonia, TB, syphilis

 endocrine:

hypothyroidism, hyperthyroidism, hypopituitarism, SIADH

 metabolic: porphyria, Wilson’s disease, diabetes

 vitamin disorders:

Wernicke’s, beriberi, pellagra, pernicious anemia

 collagen vascular diseases: SLE, polyarteritis nodosa

 neoplastic: pancreatic cancer, carcinoid, pheochromocytoma

 cardiovascular:

cardiomyopathy, CHF, MI, CVA

 neurologic:

Huntington’s disease, multiple sclerosis,

tuberous sclerosis, degenerative (vascular, Alzheimer’s)

 drugs: antihypertensives, antiparkinsonian,

hormones, steroids, antituberculous,

interferon, antineoplastic medications

Medical Workup of Mood Disorder

 routine screening:

o physical examination o complete blood

count

o thyroid function test

o electrolytes o urinalysis, urine

drug screen

 addtional screening:

o neurological consultation o chest x-ray o electrocardiogram

o CT scan

Risk Factors for Depression

 sex: female > male

 age: onset in 25-50 year age group

 family history:

depression, alcohol abuse, sociopathy

 childhood experiences:

loss of parent before age 11, negative home environment (abuse, neglect)

 personality: insecure, dependent, obsessional

 recent stressors (illness, financial, legal)

 postpartum <6 months

 lack of intimate,

confiding relationships or social isolation

DSM-IV-TR Criteria for Major Depressive Episode

A. >5 of the following symptoms have been present during the same 2-week period and represent a change from previous functioning; at least one of the

symptoms is either 1) depressed mood, or 2) loss of interest or

pleasure (anhedonia) Note: Do not include symptoms that are clearly due to a general medical condition, or mood-incongruent delusions or hallucinations

depressed mood most of the day, nearly every day, as indicated by either subjective report or observation made by others

markedly diminished interest or pleasure in all, or almost all, activities most of the day, nearly every day

significant weight loss when not dieting or weight gain, or decrease or increase in appetite nearly every day

insomnia or hypersomnia nearly every day

psychomotor agitation or retardation nearly every day

fatigue or loss of energy nearly every day

feelings of worthlessness or excessive or

inappropriate guilt (which may be

delusional) nearly every day (not merely self-reproach or guilt about being sick)

diminished ability to think or concentrate, or indecisiveness, nearly every day

recurrent thoughts of death (not just fear of dying), recurrent suicidal ideation without a specific plan, or a suicide attempt or a specific plan for committing suicide

 B. the symptoms do not meet criteria for a Mixed Episode

 C. the symptoms cause clinically significant distress or impairment in social, occupational, or

other important areas of functioning

 D. the symptoms are not due to the direct

physiological effects of a substance or a GMC

 E. the symptoms are not better accounted for by bereavement, i.e. after the loss of a loved one, the symptoms persist for longer than 2 months or are characterized by marked functional impairment, morbid preoccupation with worthlessness, suicidal ideation, psychotic symptoms, or

psychomotor retardation Criteria for Depression (>5):

MSIGECAPS

M - Depressed Mood S - Increased/decreased Sleep

I - Decreased Interest G - Guilt

E - Decreased Energy C - Decreased Concentration

A - Increased/decreased Appetite

P - Psychomotor agitation/retardation S - Suicidal ideation

In document La reforma agraria en Panamá (página 67-70)